Company profile
Travere Therapeutics, Inc.
NASDAQ:TVTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Sparsentan | approved | — | 9 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06431893 | phase3 | enrolling_by_invitation | 2024-04-30 | 2030-08-01 | Travere Therapeutics, Inc. | A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) |
| NCT03762850 | phase3 | active_not_recruiting | 2018-12-11 | 2023-08-07 | Travere Therapeutics, Inc. | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy |
| NCT06247085 | phase3 | recruiting | 2023-12-28 | 2027-08-01 | Travere Therapeutics, Inc. | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment |
| NCT05856760 | phase2 | completed | 2023-05-19 | 2024-10-14 | Travere Therapeutics, Inc. | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN |
| NCT03041116 | phase3 | terminated | 2017-07-17 | 2019-12-30 | Travere Therapeutics, Inc. | Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 216403 | NDA | TRAVERE THERAPEUTICS INC | ||||
Loading… | ||||||